CLX 0900
Latest Information Update: 29 Jan 2003
Price :
$50 *
At a glance
- Originator Calyx Therapeutics (CEASED)
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Hyperlipidaemia
Most Recent Events
- 29 Jan 2003 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
- 29 Jan 2003 Discontinued - Preclinical for Hyperlipidaemia in USA (PO)
- 30 Mar 2000 Preclinical development for Diabetes mellitus in USA (PO)